bioRxiv · Jul 1, 2026
Cardiovascular Benefits of Menopause Hormone Treatment is Age-Dependent
By Lalisan CD, Gavin C, Litts B et al.
BACKGROUND: Hormone therapy (HT) has not consistently reduced atherosclerotic cardiovascular disease (ASCVD) events in post-menopausal women, yet the underlying mechanisms remain poorly understood. METHODS: Female Ldlr -/- mice with established atherosclerosis were subjected to surgical menopause and treated with 17β-estradiol (E₂) following lipid normalization. Studies were performed in aging and young mice. To determine whether inflammation mediates the age-dependent response to HT, a cohort of aging mice underwent transplantation with Ifnγ -/- bone marrow (BM) before hormone treatments. Metabolic parameters, HDL function, systemic inflammation, atherosclerotic burden, liver metabolic and oxidative stress signaling, and hepatic estrogen receptor signaling were evaluated. RESULTS: In aging mice, menopause E₂ treatment failed to reduce established atherosclerosis as shown in sham operated mice during lipid normalization. Instead, E₂ treatment increased circulating IFNγ and IL-6, impaired HDL antioxidant and cholesterol efflux functions, and promoted inflammatory and vulnerable plaque phenotypes. Suppression of inflammation through Ifnγ -/-BM transplantation restored HDL function and significantly reduced atherosclerosis in E₂-treated aging mice. In contrast to aging mice, young mice exhibited reduced systemic and plaque inflammation, improved HDL functions and atherosclerosis following E₂ treatment. Liver RNA sequencing and qPCR validation identified activation of inflammatory, oxidative stress, and lipid metabolic pathways in aging E₂-treated mice, which were largely attenuated following Ifnγ -/- bone marrow transplantation as well as in young mice. Compared to young mice, aging mice presented hepatic estrogen receptor remodeling characterized by reduced estrogen receptor α (ERα) expression and increased G-protein coupled estrogen receptor (GPER) expression. Constitutive GPER activation was accompanied by induction of NOX1-dependent oxidative stress, which was further exacerbated by E₂ treatment, leading to persistent inflammation. CONCLUSIONS: The cardiovascular effects of estrogen therapy are fundamentally age dependent. Aging shifts estrogen signaling toward hepatic oxidative stress and inflammation through increased GPER. While E₂ treatment preserves both metabolic and cardiovascular protection in young mice, aging exacerbates GPER-NOX1-mediated oxidative stress, resulting in impaired HDL function and persistent residual ASCVD risk. These findings identify inflammation-driven, non-lipid mechanisms as potential therapeutic targets to improve cardiovascular outcomes during hormone therapy in postmenopausal women.
doi.org/10.64898/2026.06.29.734522Open accessPubMed 42427504Interventions